Bitcoin’s late-year slump has revived a familiar online refrain that the market is “controlled” and price is being suppressed but Strategy CFO Andrew Kang said Bitcoin’s late-year slump has revived a familiar online refrain that the market is “controlled” and price is being suppressed but Strategy CFO Andrew Kang said

Is The Bitcoin Price ‘Manipulated’? Strategy CFO Addresses The Rumors

Bitcoin’s late-year slump has revived a familiar online refrain that the market is “controlled” and price is being suppressed but Strategy CFO Andrew Kang said the manipulation thesis doesn’t square with Bitcoin’s scale, and that even large, highly liquid public vehicles struggle to move the needle.

Speaking on Natalie Brunell’s Coin Stories in an interview dated Dec. 30, Kang framed recent bearish sentiment as less about Bitcoin-specific weakness and more about how the asset still trades within a broader risk regime shaped by macro uncertainty, rate expectations, and tech volatility.

Is The Bitcoin Price ‘Manipulated’?

Brunell asked Kang to address speculation that Bitcoin has been manipulated “over the last quarter or so,” a narrative some commentators tie to the Oct. 10 liquidation event and the timing of an MSCI memo about potential index methodology changes for digital-asset-treasury companies.

Kang didn’t rule out that some actors may want to influence markets, but he dismissed the idea of a coordinated, systemic suppression plan as implausible at Bitcoin’s current market size.

“I honestly, you know, I think a lot of that comes from things that are fun to talk about,” Kang said. “Could there be minds that think like that? Most likely. But I think for the scale in which we operate, the magnitude of what Bitcoin is today in this market, it’s hard for any one actor to really manipulate the market. And for there to be a systemic sort of plan to do that feels a little far-reaching to me.”

He added that conspiracy narratives often get stapled to Strategy itself including claims that its equity issuance or weekly buying is “why this happened” but argued that the asset has grown beyond any single corporate treasury’s ability to steer price action meaningfully.

“The fact is Bitcoin is such a big asset class now,” Kang said. “Even Strategy has a hard time doing something that impacts it.”

The Real Reasons For BTC’s Price Action

Kang repeatedly returned to the idea that Bitcoin remains an “emerging asset,” and that volatility is a feature of its current stage of adoption rather than evidence of hidden hands. He pointed to his own entry point in 2022, a year he recalled as a harsh lesson in downside moves, and argued that today’s sentiment doesn’t look uniquely Bitcoin-driven.

“To me [the sentiment] isn’t Bitcoin specific,” Kang said, describing Bitcoin as still “viewed as a risk asset within a broader macro environment.” He cited uncertainty around Federal Reserve policy and rate expectations next year, while emphasizing that the long-term “intrinsic values” Bitcoiners cite, like finite supply and store-of-value framing, “still persist.”

In one of his most emphatic passages, Kang laid out a sweeping view of Bitcoin’s long-run trajectory as Strategy’s rationale for continuing to raise capital and add to its balance sheet.

“There’s still more upside to Bitcoin. We know it’s going to go from where it is today to, you know, back to $125K, up to $200K, up to a million, up to 21 million one day,” Kang said. “That all still is going to happen. It just is going to happen over a period of time. And there’s going to be volatility associated with it.”

At press time, BTC traded at $88,730.

Bitcoin price
Market Opportunity
Kangamoon Logo
Kangamoon Price(KANG)
$0.0001544
$0.0001544$0.0001544
-1.96%
USD
Kangamoon (KANG) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26